NCT05494398

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: an Open Label Extension

• Status: Enrolling By Invitation
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 3 Years – 13 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.

Conditions

• Autism Spectrum Disorder

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.

Timeline

• Start date: 2024-03-12
• Primary completion: 2028-07-31
• Completion: 2029-01-31
• First posted: 2022-08-10
• Last updated: 2026-01-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study